ArticleFrontiers in neurology2025
Tracking prodromal Parkinson's disease: a five-year follow-up of the PARCAS cohort.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The updated International Parkinson and Movement Disorders Society (MDS) research criteria for prodromal Parkinson's disease (pPD) enable pPD probability assessment. In the PARkinson's disease associated Colonic Alpha-Synuclein biomarker (PARCAS) study, we previously identified 12 possible (7.5%) and 10 probable (6.3%) pPD cases among 160 elderly individuals undergoing colonoscopy at baseline. Objective: To apply MDS pPD criteria in the PARCAS cohort at five-year follow-up (FU), evaluating pPD detection, longitudinal stability, and conversion rates to Parkinson's disease (PD) or other neurodegenerative diseases. Methods: We assessed all risk and prodromal markers except genetic testing; DaTscan and polysomnography (PSG)-confirmed idiopathic REM sleep behavior disorder (iRBD) were available only in a subset of participants. Criteria accuracy was retrospectively evaluated in phenoconverters. Results: Among 87/160 participants completing FU, 3 possible (3.5%) and 6 probable (7%) pPD cases were detected. Most remained stable in pPD classification (73 negative, 2 possible, 2 probable pPD), while 4 regressed and 5 progressed in their risk category. Two patients converted to PD and one to corticobasal syndrome (CBS). Baseline sensitivity was 0% at 80% probable pPD threshold (rising to 66% at 50% possible pPD threshold) and reached 100% at 80% threshold at FU. Conclusion: pPD probability showed high agreement between baseline and FU assessments. However, absence of key specific markers (PSG-confirmed iRBD and DaTscan) limited baseline sensitivity, which improved only near phenoconversion as additional prodromal symptoms accumulated. Identification of a prodromal CBS case illustrates the potential for detection of atypical parkinsonisms, even with non-α-synuclein pathology, suggesting limited specificity for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.